2015-11-13T07:49:40-06:00 2014-12-31 KPMG LLP 60 South Street Boston MA 02111 990 2014-01-01 010211513 THE JACKSON LABORATORY % LINDA A JENSEN JACK 2072886000 600 MAIN STREET BAR HARBOR ME 04609 LINDA JENSEN CFO 2072886000 2015-11-12 true TARA D'AGOSTINO P01245482 6179881000 2014 2016-02-25 16:41:14Z EDISON LIU 600 MAIN STREET BAR HARBOR ME 04609 292228376 false X WWW.JAX.ORG X 1929 ME WE DISCOVER PRECISE GENOMIC SOLUTION FOR DISEASE AND EMPOWER THE GLOBAL BIOMEDICAL COMMUNITY IN THE SHARED QUEST TO IMPROVE HUMAN HEALTH. 23 21 1992 52 -41605 -57641 74310661 91256682 161752623 181040415 15332676 12579453 5736826 6712934 257132786 291589484 17500 2526000 0 0 114591517 129338203 130573 241427 3474538 101389780 118463524 216129370 250569154 41003416 41020330 612525781 736361322 195747777 243375369 416778004 492985953 X WE DISCOVER PRECISE GENOMIC SOLUTIONS FOR DISEASE AND EMPOWER THE GLOBAL BIOMEDICAL COMMUNITY IN THE SHARED QUEST TO IMPROVE HUMAN HEALTH. false false 108079437 26000 180377185 DEVELOP AND PROVIDE GENETIC RESOURCES - PLEASE SEE SCHEDULE O FOR DETAIL. 95030631 2500000 172065 BIOMEDICAL RESEARCH - PLEASE SEE SCHEDULE O FOR DETAIL 5688217 491165 EDUCATION AND TRAINING - PLEASE SEE SCHEDULE O FOR DETAIL 196240 208798285 true true false true false false false false false true true false false false true true true false false true true false false true true false false true false true true false false false false false false false false true true true false false false false false false false false true 175 0 true 1992 true true true false false false false true true false false false false X 23 21 false false false false false false false true true false false true true true true true true true true false AL AZ CA CT DE FL GA IL IA ME MD MA MN NY PA SC X X X LINDA A JENSEN 2072886108 600 MAIN STREET BAR HARBOR ME 04609 EDISON T LIU MD CHIEF EXECUTIVE OFFICER 40.0 0.0 X X 867017 0 127921 CHARLES E HEWETT PHD EXECUTIVE VICE PRESIDENT 40.0 0.0 X X 661131 0 296443 DAVID BALTIMORE PHD TRUSTEE 1.0 0.0 X 0 0 0 DAVID R CABOT TRUSTEE 1.0 0.0 X 0 0 0 KATHLEEN A CORBET TRUSTEE 1.0 0.0 X 0 0 0 LOUIS J D'AMBROSIO TRUSTEE 1.0 0.0 X 0 0 0 DAVID D ELLIMAN TRUSTEE 1.0 0.0 X 0 0 0 ANTHONY B EVNIN PHD TRUSTEE 1.0 0.0 X 0 0 0 JAMES J GALLOGLY TREASURER 1.0 0.0 X X 0 0 0 PETER F GERRITY SECRETARY 1.0 0.0 X X 0 0 0 RICHARD S GURIN TRUSTEE 1.0 0.0 X 0 0 0 LEO A HOLT CHAIR OF BOARD 1.0 0.0 X X 0 0 0 WESLIE R JANEWAY VICE CHAIR OF BOARD 1.0 0.0 X X 0 0 0 RICHARD S LANNAMANN TRUSTEE 1.0 0.0 X 0 0 0 SAM R LITTLE TRUSTEE 1.0 0.0 X 0 0 0 NEAL B MILCH JD TRUSTEE 1.0 0.0 X 0 0 0 DENNIS PAUSTENBACH PHD TRUSTEE 1.0 0.0 X 0 0 0 CHARLES M RICE PHD TRUSTEE 1.0 0.0 X 0 0 0 JANET ROSSANT PHD TRUSTEE 1.0 0.0 X 0 0 0 DAVID J ROUX TRUSTEE 1.0 0.0 X 0 0 0 EDWARD RUBIN MD PHD TRUSTEE 1.0 0.0 X 0 0 0 JOAN A STEITZ PHD TRUSTEE 1.0 0.0 X 0 0 0 DAVID VALLE MD TRUSTEE 1.0 0.0 X 0 0 0 THOMAS S VOLPE TRUSTEE 1.0 0.0 X 0 0 0 BRIAN F WRUBLE TRUSTEE 1.0 0.0 X 0 0 0 LINDA A JENSEN MS CHIEF FINANCIAL OFFICER 40.0 0.0 X 347980 0 52160 BRIAN R LESLIE GENERAL COUNSEL 40.0 0.0 X 412654 0 44808 JAY VETELINO ASSISTANT TREASURER 40.0 0.0 X 114525 0 35883 ROBERT E BRAUN PHD VICE PRESIDENT RESEARCH 40.0 0.0 X 354471 0 36612 LEAH RAE B DONAHUE PHD DIR GENETIC RESOURCE SCIENCE 40.0 0.0 X 161353 0 33693 CHARLES LEE MD SCIENTIFIC DIRECTOR, JAX GM 40.0 0.0 X 351329 0 54368 AUROBINDO NAIR PHD GM SCIENTIFIC RESEARCH SVCS 40.0 0.0 X 397510 0 56682 KATHY L VANDEGRIFT ASSOCIATE GENERAL MANAGER 40.0 0.0 X 300045 0 47124 MICHAEL HYDE VP EXTERNAL AFFAIRS 40.0 0.0 X 312830 0 75904 JACQUES F BANCHEREAU PHD PROFESSOR 40.0 0.0 X 373518 0 48644 ETZARD STOLTE PHD CHIEF INFOMRATION OFFICER 40.0 0.0 X 324805 0 70359 KRISTEN B ROZANSKY VP DEVELOPMENT & COMMUNICATION 40.0 0.0 X 359489 0 51113 JOHN FITZPATRICK SENIOR DIRECTOR, FACILITIES 40.0 0.0 X 268668 0 71201 YIJUN RUAN PHD DIRECTOR, JAX GM 40.0 0.0 X 251660 0 48708 5858985 0 1151623 154 false true false FUSION CONSULTING INC 5215 N OCONNER BLVD IRVING TX 75039 IT CONSULTING 955036 STARLIMS CORPORATION 4000 HOLLYWOOD BLVD HOLLYWOOD FL 33021 IT CONSULTING 907812 GILBANE BUILDING COMPANY 7 JACKSON WALKWAY PROVIDENCE RI 02903 CONSTRUCTION MGMT 716742 CENTERBROOK ARCHITECT PO BOX 955 CENTERBROOK CT 06409 ARCHITECT 605845 DIGITAL CONSULTING AND SOFTWARE SVC 2277 PLAZA DRIVE SUGAR LAND TX 77479 SOFTWARE CONSULTING 446771 18 97528 77323736 13835418 2372521 91256682 GENETIC RESOURCES 541700 180377185 180377185 TRAINING & EDUCATION 541700 491165 491165 RESEARCH 541700 172065 172065 181040415 3788774 -7689 3796463 0 6627044 6627044 0 0 0 0 0 9143383 207579 313750 246533 8829633 -38954 8790679 8790679 2175 97528 78609 -76434 -76434 0 0 0 OTHER REVENUE 900099 196240 196240 DEBT FINANCED RENTAL INCOME 531390 -33916 -33916 162324 291589484 181236655 -41605 19137752 2526000 2526000 0 0 0 4753707 338827 4414880 0 92487219 76082499 15433940 970780 6975345 6188666 707443 79236 18295275 12783793 5314595 196887 6826657 5615794 1139208 71655 0 919064 86637 831469 958 204165 25000 179165 447156 447156 241427 241427 292990 292990 12755125 10186473 1992154 576498 986454 913997 71235 1222 2278152 1399913 704908 173331 5784690 4786563 930042 68085 161786 161786 12272561 11080720 1097524 94317 5370946 4028087 1019938 322921 0 353404 296020 56505 879 3988732 3769128 186727 32877 0 27510673 24711203 2341473 457997 1572623 1465260 94999 12364 SUPPLIES 40373731 39569398 676608 127725 OTHER SERVICES 1796799 1573785 216928 6086 STIPENDS 777423 774923 2500 EQUIPMENT RENTAL 516220 345475 136142 34603 100830 88338 10302 2190 250569154 208798285 38296331 3474538 25000 25000 121799993 152005357 6944458 10011476 18160263 25606040 0 0 0 0 400000 0 2534227 3065793 5116981 5133276 637123692 239233339 329032362 397890353 64791916 111467212 44173801 15142592 0 0 0 0 19546780 16014223 612525781 736361322 42712651 48317692 0 0 7289540 9725794 106014868 104647760 0 0 0 0 27720155 67540155 0 0 12010563 13143968 195747777 243375369 X 369076773 439085978 37321434 38570318 10379797 15329657 416778004 492985953 612525781 736361322 X 41020330 -5269200 1642 40455177 X false true X true true true X 73823292 41644804 67271113 74310661 91256682 348306552 0 0 73823292 41644804 67271113 74310661 91256682 348306552 19638135 328668417 2954194 2311932 2888204 7196139 10415818 25766287 48973 33525 3588 86086 18635 220423 225566 255201 164499 884324 375043249 738588548 0.87635 0.94321 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true true true true false true 447156 false false 447156 false LOBBYING ACTIVITY BY NON-ELECTING 501(C)(3) ORGANIZATION PART II-B, LINE 1G THE TOTAL LOBBYING EXPENSE FOR THE YEAR ENDED DECEMBER 31, 2014 WAS $447,156, WHICH WAS AN ALLOCATION OF EMPLOYEE COMPENSATION FOR LOBBYING ACTIVITIES AND $51,785 FOR AN ENGAGEMENT WITH THE PETRIZZO GROUP INC., OF WASHINGTON DC. 108965719 11841924 5890303 88135 126609811 90755276 6074191 13007247 870995 108965719 80841065 1280959 9091700 458448 90755276 87452850 74725 -5827854 858656 80841065 74765000 2345649 10790669 448468 87452850 0.64620 0.09160 0.26220 false false 7193452 7193452 479567323 156661903 322905420 126693187 82571436 44121751 23669730 23669730 397890353 0 RETIREMENT PLAN OBLIGATIONS 6334938 INTEREST RATE SWAP 6809030 13143968 X 326518502 -5269200 1642 40455177 35187619 291330883 337210 -78609 258601 291589484 250310553 78609 78609 250231944 337210 337210 250569154 ENDOWMENT FUNDS PART V, LINE 4 THE INVESTMENT AND SPENDING POLICIES FOR THE ENDOWMENT ASSETS HAVE BEEN ESTABLISHED TO PROVIDE A PREDICTABLE STREAM OF FUNDING FOR THE PROGRAMS SUPPORTED BY ENDOWMENT INCOME, WHILE SEEKING TO MAINTAIN THE PURCHASING POWER OF THE ENDOWMENT ASSETS. IN ADDITION, WHEN CONSIDERING THE AMOUNT OF INCOME TO APPROPRIATE FROM BOARD-DESIGNATED ASSETS, THE TRUSTEES CONSIDER THE NEED TO MAINTAIN UNRESTRICTED ASSETS TO MEET LIQUIDITY COVENANTS RELATED TO OUTSTANDING BONDS. ACCORDINGLY, THE BOARD OF TRUSTEES HAS SET THE INVESTMENT ALLOCATION TO ACHIEVE A NOMINAL RATE OF RETURN THAT WILL AT LEAST COVER INFLATION AND THE SPEND RATE WITH A PRUDENT LEVEL OF RISK. THE INVESTMENT ALLOCATION FOR THE BOARD-DESIGNATED PORTION OF THE ENDOWMENT IS SET TO ACHIEVE GREATER STABILITY IN THE VALUE OF INVESTMENTS. THE BOARD ALLOCATED 4% OF THE THREE YEAR AVERAGE VALUE OF DONOR-DESIGNATED ENDOWMENT BALANCES TO SUPPORT THE DESIGNATED PROGRAMS. ALL EARNINGS ON DONOR ENDOWMENTS ESTABLISHED TO PROVIDE GENERAL SUPPORT FOR THE LABORATORY AS APPROVED BY THE BOARD OF TRUSTEES WERE RETAINED IN THE ENDOWMENT. THE BOARD OF TRUSTEES WISHES TO INCREASE THE AMOUNT OF ENDOWMENT SUPPORT AVAILABLE IN THE FUTURE. LIABILITY FOR UNCERTAIN TAX POSITIONS UNDER FIN 48 (ASC 740) PART X, LINE 2 THE LABORATORY IS A NOT-FOR-PROFIT ORGANIZATION AS DESCRIBED IN SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE (THE CODE), AS AMENDED, AND IS GENERALLY EXEMPT FROM INCOME TAXES PURSUANT TO THE CODE. IN ACCORDANCE WITH GAAP, THE LABORATORY ASSESSES WHETHER THERE ARE UNCERTAIN TAX POSITIONS AND DETERMINED THERE WERE NO UNCERTAIN TAX POSITIONS THAT WOULD HAVE A MATERIAL EFFECT ON THE FINANCIAL STATEMENTS. OTHER REVENUE ON FINANCIAL STATEMENTS NOT ON RETURN PART XI, LINE 2D UNREALIZED LOSS ON INTEREST RATE SWAPS (1,461,708) CHANGES IN ACTUARIAL ASSUMPTIONS 79,795 FAIR MARKET VALUE ADJUSTMENT ON LOANS 41,837,090 TOTAL 40,455,177 OTHER REVENUE ON RETURN NOT IN FINANCIAL STATEMENTS PART XI, LINE 4B RECLASS OF FUNDRAISING EXPENSES (78,609) OTHER EXPENSES INCLUDED IN FINANCIAL STATEMENT NOT ON RETURN PART XII, LINE 2D RECLASS OF FUNDRAISING EXPENSES 78,609 Europe (Including Iceland and Greenland) 2 Program Services GENETIC RESOURCES 116170 East Asia and the Pacific Program Services GENETIC RES. COURSES 29598 Europe (Including Iceland and Greenland) Program Services SURGERY WORKSHOP 25499 Central America and the Caribbean Investments 11628372 East Asia and the Pacific Program Services GENETIC RESOURCES Europe (Including Iceland and Greenland) Program Services GENETIC RESOURCES Middle East and North Africa Program Services GENETIC RESOURCES North America Program Services GENETIC RESOURCES Russia and the Newly Independent States Program Services GENETIC RESOURCES South America Program Services GENETIC RESOURCES South Asia Program Services GENETIC RESOURCES Sub-Saharan Africa Program Services GENETIC RESOURCES 2 2 11799639 11799639 true false true false false true X X X X X X X true GRENZEBACH AND GLIER ASSOC 401 N Michigan Avenue CHICAGO IL 60611 CONSULTANT false 0 241427 -241427 0 241427 -241427 CA CT FL ME MA NY PA DISCOVERY DAYS 82850 80675 2175 67509 COOKIE'S RIDE 15353 15353 4463 3 1500 1500 6637 99703 97528 2175 78609 78609 -76434 true NEW YORK GENOME CENTER 101 AVENUE OF THE AMERICAS 7TH FLOOR SUITE NEW YORK NY 10013 800631734 501(C)(3) 2500000 SUPPORT MAINE MATHEMATICS AND SCIENCE ALLIANCE 219 CAPITOL STREET NO 3 AUGUSTA ME 04330 223181644 501(c)(3) 10000 SUPPORT GRAND AERIE FRATERNAL ORDER OF EAGLES 13410 W FOXFIRE DR SURPRISE AZ 85378 390920675 501(C)(8) 10000 SUPPORT 2 1 MONITOR THE USE OF GRANT FUNDS PART I, LINE 2 THE ALLOCATION OF GRANTS AND OTHER ASSISTANCE TO LOCAL ORGANIZATIONS IS DETERMINED ON AN ANNUAL BASIS. X true true X X X X X true true false false false false false true false EDISON T LIU MD CHIEF EXECUTIVE OFFICER 750287 0 100000 0 16730 0 101000 0 26921 0 994938 0 0 0 CHARLES E HEWETT PHD EXECUTIVE VICE PRESIDENT 522342 0 50000 0 88789 0 269000 0 27443 0 957574 0 54828 0 LINDA A JENSEN MS CHIEF FINANCIAL OFFICER 291256 0 40000 0 16724 0 24500 0 27660 0 400140 0 0 0 BRIAN R LESLIE GENERAL COUNSEL 315472 0 71250 0 25932 0 26000 0 18808 0 457462 0 0 0 JAY VETELINO ASSISTANT TREASURER 114525 0 0 0 0 0 11916 0 23967 0 150408 0 0 0 ROBERT E BRAUN PHD VICE PRESIDENT RESEARCH 310175 0 10000 0 34296 0 24500 0 12112 0 391083 0 0 0 LEAH RAE B DONAHUE PHD DIR GENETIC RESOURCE SCIENCE 122647 0 30000 0 8706 0 12173 0 21520 0 195046 0 0 0 CHARLES LEE MD SCIENTIFIC DIRECTOR, JAX GM 297256 0 48000 0 6073 0 25625 0 28743 0 405697 0 0 0 AUROBINDO NAIR PHD GM SCIENTIFIC RESEARCH SVCS 298122 0 65381 0 34007 0 24485 0 32197 0 454192 0 0 0 KATHY L VANDEGRIFT ASSOCIATE GENERAL MANAGER 238755 0 57950 0 3340 0 22722 0 24402 0 347169 0 0 0 MICHAEL HYDE VP EXTERNAL AFFAIRS 259748 0 18000 0 35082 0 38373 0 37531 0 388734 0 0 0 JACQUES F BANCHEREAU PHD PROFESSOR 334602 0 35000 0 3916 0 28593 0 20051 0 422162 0 0 0 ETZARD STOLTE PHD CHIEF INFOMRATION OFFICER 182792 0 75000 0 67013 0 19892 0 50467 0 395164 0 0 0 KRISTEN B ROZANSKY VP DEVELOPMENT & COMMUNICATION 324224 0 32000 0 3265 0 23685 0 27428 0 410602 0 0 0 JOHN FITZPATRICK SENIOR DIRECTOR, FACILITIES 170000 0 91250 0 7418 0 26000 0 45201 0 339869 0 0 0 YIJUN RUAN PHD DIRECTOR, JAX GM 247999 0 0 0 3661 0 24243 0 24465 0 300368 0 0 0 BENEFITS PART I, LINE 1A TAX INDEMNIFICATION AND GROSS-UP PAYMENTS: THE JACKSON LABORATORY GROSSES UP THE AMOUNT ADDED TO WAGES FOR IMPUTED INSURANCE PREMIUMS FOR THE SENIOR MANAGEMENT GROUP TO COVER TAXES. THE LABORATORY ALSO GROSSES UP WAGES TO COVER THE TAX IMPACT OF GIFT CARDS AND OTHER AWARDS OR PRIZES TO EMPLOYEES SO THAT THE RECIPIENTS RECEIVE THE FULL VALUE OF THE GIFT OR AWARD. SEVERANCE PAYMENT PART I, LINE 4A THE JACKSON LABORATORY PAID SEVERANCE OF $62,500 TO ETZARD STOLTE, PHD DURING THE YEAR. SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN PART I, LINE 4B THE LABORATORY MAINTAINS A DEFERRED COMPENSATION PLAN UNDER SECTION 457(F). THE PRESIDENT/CEO AND EXECUTIVE VICE PRESIDENT/COO PARTICIPATE IN A NON-QUALIFIED SUPPLEMENTAL RETIREMENT PLAN THAT PROVIDES FOR A PORTION OF THEIR COMPENSATION TO BE DEFERRED UNDER A SECTION 457 (F) PLAN. THE PRESIDENT/CEO DEFERRED $75,000 AND THE EXECUTIVE VICE PRESIDENT/COO DEFERRED $75,000 UNDER THIS PLAN DURING CALENDAR YEAR 2014. THE EXECUTIVE VICE PRESIDENT/COO RECEIVED A PAYOUT OF $54,828. NON-FIXED PAYMENTS PART I, LINE 7 THE TOTAL COMPENSATION PACKAGE OF CERTAIN OFFICERS, KEY EMPLOYEES, AND OTHER EMPLOYEES INCLUDES VARIABLE COMPENSATION AWARDED BASED ON PERFORMANCE. A ABAG FINANCE AUTHORITY FOR NONPROFIT CORPORATION 943130123 00037CLX6 2007-09-12 35075000 FINANCE CONSTRUCTION & REFUND true false false B FINANCE AUTHORITY OF MAINE 042456011 2012-08-31 42460000 REFUND false false false C ABAG FINANCE AUTHORITY FOR NONPROFIT CORPORATIONS 943130123 00037CTH3 2012-10-24 66355769 FINANCE CONSTRUCTION & REFUND false false false A 275000 32475000 35075000 0 1004292 0 456682 0 0 31597588 2016438 0 2009 true false true true B 1795000 0 42460000 0 0 0 0 0 0 0 42460000 0 2002 true false true true C 1170000 0 66432099 0 0 35471128 623401 0 0 26665257 3672313 0 2015 false true false true A false false true true true true 0.00497 0.00000 0.00497 false false 0.00000 false false B false false false true true 0.00082 0.00000 0.00082 false false false false C false false true true true true 0.00685 0.00000 0.00685 false false false false A false false false true false false 0 false 0 false false B false false false true true false 0 false 0 false false C false true false false false false 0 false 0 false false A true B true C true BOND PROCEEDS - BOND ISSUE C PART II, LINE 3 THE DIFFERENCE IN ISSUE PRICE AND LINE 3 PROCEEDS FOR BOND ISSUE C IS INTEREST INCOME FROM THE AMOUNTS HELD IN THE REFUNDING ESCROW ACCOUNT. PART IV, LINE 2(C) BOND ISSUE A - NO REBATE DUE, ARBITRAGE CALCULATION PERFORMED 10/03/13 BY AMTEC (REFLECTING ACTIVITY THROUGH 08/31/13). BOND ISSUE B - NO REBATE DUE, ARBITRAGE CALCULATION PERFORMED 01/23/14 BY AMTEC (REFLECTING ACTIVITY THROUGH 10/31/13). BANGOR SAVINGS BANK OFFICER - CHARLES HEWETT 1225658 CREDIT CARD PROCESSING FEES false MADELEINE BRAUN PHD KEY EMPLOYEE-ROBERT BRAUN 195816 EMPLOYMENT - FAMILY MEMBER false X 30 2372521 FMV false true false CONTRIBUTIONS PART I, COLUMN B THE NUMBER OF CONTRIBUTIONS ARE REPORTED IN COLUMN B. ORGANIZATION'S MISSION FORM 990, PART III, LINE 1 THE MISSION OF THE LABORATORY IS TO DISCOVER PRECISE GENOMIC SOLUTIONS FOR DISEASE AND EMPOWER THE GLOBAL BIOMEDICAL COMMUNITY IN THE SHARED QUEST TO IMPROVE HUMAN HEALTH. TO ACCOMPLISH THIS MISSION THE LABORATORY 1) CONDUCTS BASIC BIOMEDICAL RESEARCH TO INCREASE THE KNOWLEDGE OF DEVELOPMENT, GROWTH, REPRODUCTION, PHYSIOLOGICAL, AND GENETICALLY DETERMINED AILMENTS THROUGH RESEARCH WITH GENETICALLY DEFINED EXPERIMENTAL ANIMALS; 2) CONDUCTS TRANSLATIONAL BIOMEDICAL RESEARCH TO IDENTIFY THE GENOMIC BASIS FOR HUMAN DISEASE, PROMOTE THE ESTABLISHMENT OF MORE PRECISE, TARGETED THERAPIES, AND OFFER CUTTING EDGE GENOMIC DIAGNOSTICS TO THE MEDICAL COMMUNITY; 3) TRAINS AND EDUCATES SCIENTISTS, PHYSICIANS, AND OTHER PROFESSIONALS IN THESE AREAS; AND 4) PROMOTES SCIENTIFIC DISCOVERY THROUGH THE PROVISION OF MOUSE MODELS OF HUMAN DISEASE AND THE PROVISION OF RESEARCH AND CLINICAL SERVICES TO THE GLOBAL SCIENTIFIC AND MEDICAL COMMUNITY. THE LABORATORY ALSO WORKS TO ACCELERATE THE TRANSLATION OF DISCOVERIES MADE IN BASIC RESEARCH TO TREATMENTS FOR HUMAN DISEASE. PROGRAM SERVICES FORM 990, PART III, LINE 4A-4C 4A. GENETIC RESOURCES AND SERVICES ACCOMPLISHMENTS JAX PROVIDES THE SCIENTIFIC COMMUNITY WITH MOUSE GENETIC RESOURCES, RELATED TECHNOLOGIES, AND INFORMATION THAT SUPPORTS THEIR USE. THIS INCLUDES CONDUCTING PEER-REVIEWED, RESOURCE-GENERATING RESEARCH AND MANAGING THE MOUSE REPOSITORY, A COLLECTION OF OVER 7,000 UNIQUE STRAINS, MANY OF WHICH ARE AVAILABLE ONLY FROM JAX. JAX DEVELOPS MOUSE MODELS FOR HUMAN DISEASE, BEGINNING WITH DISCOVERIES OF SPONTANEOUS MUTANTS FROM JAX PRODUCTION COLONIES AND INCLUDING THE OPTIMIZATION OF MODELS ACQUIRED BY THE REPOSITORY. THIS EFFORT INCLUDES ENGINEERING NEW MODELS FOR OUR OWN HYPOTHESIS-DRIVEN RESEARCH. DURING 2014 THE LABORATORY CREATED NEW MODELS WHICH INCLUDED 15 FOR PEDIATRIC CONGENITAL HEART DISEASE AND 2 TRANSGENIC MODELS FOR PARKINSON'S DISEASE. JAX HAS A PILOT PROJECT TO USE CRISPR/CAS9 TECHNOLOGY FOR SELECTED TARGET GENES AT SCALE, PROVIDING KEY OPERATIONAL DATA TO ASSESS THE FEASIBILITY OF INCORPORATING SITE-SPECIFIC NUCLEASE TECHNOLOGY INTO THE NEXT PHASE OF THE PROGRAM. IN ADDITION SMALLER SCALE PILOT EXPERIMENTS OPTIMIZE NON-ROUTINE GENETIC ENGINEERING, INCLUDING THE CREATION OF HUMAN DISEASE ALLELES, CONDITIONAL ALLELES AND REPORTER KNOCK-INS. JAX ACHIEVED AN 85% SUCCESS RATE FOR INJECTION ATTEMPTS SCREENED; BY COMPARISON TRADITIONAL METHODS HAVE AN AVERAGE 57% SUCCESS RATE. THE MOUSE MUTANT RESOURCE (MMR) IS THE JACKSON LABORATORY'S PRIMARY REPOSITORY FOR THE ACQUISITION AND CHARACTERIZATION OF MICE CARRYING SPONTANEOUS, DISEASE-CAUSING MUTATIONS. IN 2014 FIFTY-FIVE (55) OVERLAPPING STRAINS HAVE BEEN GENETICALLY MAPPED AND ANALYZED BY WES. TWENTY-ONE (21) IDENTIFIED MUTATIONS WERE VALIDATED OVER THE LAST YEAR AND, SEVENTEEN (17) WERE CLASSIFIED AS NEW ALLELES OF GENES WITH PRIOR EXISTING MUTATIONS. FOUR (4) WERE CLASSIFIED AS MUTATIONS IN GENES FOR WHICH NO PHENOTYPE-CAUSING VARIANT HAD PREVIOUSLY BEEN OBSERVED. FINALLY, TO ASSAY SPECIFIC GENE MUTATIONS WITHIN MMR MICE AND TO MAKE NEW MMR STRAIN DEVELOPMENT KNOWN TO THE SCIENTIFIC COMMUNITY, NINETEEN (19) MOLECULAR ASSAYS WERE DEVELOPED, TWELVE (12) ONLINE PUBLICATIONS WERE POSTED TO THE MMR WEBSITE AND THIRTEEN (13) STRAINS WERE MADE PUBLIC THROUGH MOUSE GENOME INFORMATICS (MGI) DIRECT DATA SUBMISSION. WHILE JAX DEVELOPS NEW MOUSE MODELS IN HOUSE, THE REPOSITORY'S MAJOR SOURCE OF NEW MOUSE STRAINS IS THE STRAIN ACQUISITION PROGRAM. ACQUISITION ADDED APPROXIMATELY 600 STRAINS IN 2014, INCREASING THE SIZE OF THE JAX COLLECTION TO OVER 7,800 INDIVIDUAL MOUSE LINES. A KEY COMPONENT OF THE ACQUISITION PROCESS IS THE WORK DONE BY A TEAM OF CURATORS WHO ARE RESPONSIBLE FOR INTERACTING WITH DONATING LABORATORIES TO OBTAIN TECHNICAL INFORMATION AND ARRANGE IMPORTATION. CURATORS ASSIMILATE INFORMATION FROM DONATING RESEARCHERS AND PUBLISHED LITERATURE TO COMPOSE A "USER MANUAL" FOR EACH LINE. THIS INFORMATION IS ADDED TO THE JAXMICE CATALOGUE FOR USE BY THE SCIENTIFIC COMMUNITY. JAX OFFERS ONE OF THE MOST EXTENSIVE AND DIVERSE MOUSE RESOURCES IN EXISTENCE, ALLOWING US TO SUPPORT A WIDE ARRAY OF RESEARCH AND TO PRESERVE STRAINS THAT OTHERWISE MIGHT BE LOST. THE JAX CRE REPOSITORY IS AN INTEGRATED EFFORT TO GENERATE, CHARACTERIZE AND DISTRIBUTE CRE DRIVER TOOL STRAINS TO THE SCIENTIFIC COMMUNITY. THESE STRAINS ALLOW SCIENTISTS TO GENERATE PRECISE GENE DELETIONS IN A SPECIFIC ORGAN AT A SPECIFIC TIME. THE JAX CRE REPOSITORY CURRENTLY COMPRISES OVER 300 OF THESE STRAINS THAT COMPLEMENT OUR COLLECTION OF >500 "KNOCKOUT READY" STRAINS. WE EMPLOY A COMPREHENSIVE, HIGH-THROUGHPUT CRE DRIVER STRAIN CHARACTERIZATION PIPELINE, WHICH INCLUDES TWO EMBRYONIC AND TWO POSTNATAL TIME POINTS, TO PROVIDE EXTENDED FUNCTIONAL DATA FOR END USERS. ALL IMAGE AND ANNOTATION DATA IS AVAILABLE THROUGH OUR WEBSITE AND A NEW DATABASE DEVELOPED BY MGI AT JAX, CREPORTAL.ORG. THE CRE REPOSITORY WEBSITE IS ONE OF THE MOST HEAVILY VISITED SECTIONS OF ALL JAX WEBSITES, WITH OVER 120,000 PAGEVIEWS PER YEAR. CHARACTERIZATION DATA WEBPAGES SEE ESPECIALLY HEAVY TRAFFIC, DEMONSTRATING THAT THIS VALUE-ADDED INFORMATION IS BEING ACTIVELY EMPLOYED BY CRE MOUSE USERS. A MAJORITY OF THE STRAINS PRODUCED BY THE KNOCKOUT MOUSE PROJECT (KOMP2) AND INTERNATIONAL PHENOTYPING PROGRAMS CAN BE MODIFIED BY CRE TOOL STRAINS, SO THE LABORATORY IS WORKING TO ALIGN THE JAX CRE REPOSITORY WITH THIS EFFORT. TWO PROJECTS TOWARDS THIS END ARE UNDERWAY. THE FIRST LEVERAGES THE CAPACITY OF THE JAX KOMP2 PHENOTYPING CENTER TO DETERMINE IF POPULAR CRE STRAINS DISPLAY POTENTIALLY CONFOUNDING PHENOTYPES. THIS SET OF STRAINS COMPRISES THOSE WITH HIGH DISTRIBUTION HISTORY AND OTHERS OF SPECIFIC INTEREST. TEN STRAINS HAVE COMPLETED TESTING AND DATA ANALYSIS IS UNDERWAY. THE SECOND PROJECT IS BACKCROSSING AN OVERLAPPING SET TO C57BL/6NJ, PROVIDING A COMPLEMENTARY RESOURCE ON THE SAME GENETIC BACKGROUND AS THE KOMP2 RESOURCE. THE PRODUCTION GOAL IS TO PRODUCE 833 NEW STRAINS TO THE JAX KOMP2 PHENOTYPING PROJECT AND IN 2014 PASS THE 75% MARK WITH OVER 695 NEW KNOCK OUT MICE. KNOCKOUT MOUSE EMBRYONIC PHENOTYPING PIPELINE - UP TO ONE THIRD OF KNOCKOUT MICE GENERATED AS PART OF THE KOMP2 PROGRAM ARE PREDICTED TO BE EMBRYONIC LETHAL. UNDERSTANDING THE CAUSES OF EMBRYONIC LETHALITY CANNOT BE CAPTURED BY AN ADULT MOUSE PHENOTYPING PARADIGM, YET WOULD PROVIDE TREMENDOUS INSIGHT INTO GENE FUNCTION. SUBSEQUENT DETAILED ANALYSIS PROMISES TO SHED LIGHT ON THE GENES AND PROCESSES THAT, WHEN ALTERED, ARE RESPONSIBLE FOR HUMAN BIRTH DEFECTS. PRE- OR PERINATAL DEATH CAN RESULT FROM A WIDE VARIETY OF DEFECTS AT VARIOUS STAGES DURING GESTATION; HOWEVER THESE CLUSTER AT SEVERAL CRITICAL TIME POINTS WHICH CAN BE USED TO BUILD AN EFFICIENT CHARACTERIZATION SCHEME FOR HIGH THROUGHPUT PROGRAMS SUCH AS KOMP2. WORKING WITH THE INTERNATIONAL MOUSE PHENOTYPING CONSORTIUM (IMPC), WE HAVE DEVELOPED A STANDARDIZED EMBRYONIC LETHAL PHENOTYPING PIPELINE THAT MAXIMIZES THE NUMBER OF PHENOTYPES SCORED IN AN EFFICIENT, COST-EFFECTIVE MANNER. IN ADDITION TO GROSS ASSESSMENT AND EXPERT THIS INCLUDES HIGH RESOLUTION, THREE-DIMENSIONAL IMAGING AT MULTIPLE STAGES OF DEVELOPMENT. EVALUATION OF PHENOTYPES, THIS WORK WILL COMPLEMENT AND EXTEND THE CATALOGUE OF MOUSE PHENOTYPE DATA PROVIDED BY THE KOMP2 PROGRAM. TOOLS FOR STUDYING PARENT-OF-ORIGIN EFFECTS IN TURNER AND DOWN SYNDROMES - IN COLLABORATION WITH THE UNIVERSITY OF CONNECTICUT, JAX DERIVED A PANEL OF MOUSE EMBRYONIC STEM CELLS FROM TWO MOUSE MODELS OF TURNER SYNDROME; JAX#001529 C3H/HESN-PAF/J ('PAF') AND JAX#00919 IN(X)1X/J ('INX'). TURNER SYNDROME IS A GENETIC CONDITION CAUSED BY A COMPLETE OR PARTIAL ABSENCE IN FEMALES OF THE SECOND X CHROMOSOME (MONOSOMY). AFFECTED XO FEMALES SUFFER FROM A VARIETY OF DEVELOPMENTAL DISABILITIES INCLUDING GONADAL DYSGENESIS, SHORT STATURE, HEART DEFECTS AND LEARNING DISABILITIES. THERE IS EVIDENCE THAT THE ORIGIN OF THE SINGLE X CHROMOSOME IN XO FEMALES HAS AN IMPACT ON CERTAIN FEATURES OF THE DISEASE. FOR EXAMPLE, A MATERNALLY INHERITED X CHROMOSOME (XM) IS ASSOCIATED WITH MORE ADVANCED SOCIAL IMPAIRMENT AND AUTISM. DEPENDING ON THE GENETIC CROSS, PAF AND INX MICE CAN BE USED TO GENERATE XMO OR XPO OFFSPRING. JAX TOOK ADVANTAGE OF THIS TO CREATE XMO AND XPO ES CELL LINES THAT CAN BE USED TO STUDY THE MECHANISM OF PARENT-OF-ORIGIN EFFECTS AND THEIR IMPACT ON IN VITRO DIFFERENTIATED NEURONAL LINEAGES.SIMILARLY, JAX ALSO DERIVED MES CELLS FROM A MOUSE MODEL OF DOWN SYNDROME, TS65DN, WHICH CARRIES THREE COPIES OF THE REGION OF MOUSE CHROMOSOME 16 THAT IS HIGHLY CONSERVED AND HYPOTHESIZED TO BE HOMOLOGOUS WITH HUMAN CHROMOSOME 21. DOWN SYNDROME IS DUE TO THE PRESENCE OF AN EXTRA COPY OF CHROMOSOME 21 (TRISOMY 21), AND THE PARENTAL ORIGIN OF THE THIRD CHROMOSOME CAN HAVE AN IMPACT ON THE DISEASE; FOR EXAMPLE, INDIVIDUALS WITH A MATERNALLY DERIVED CHROMOSOME 21 HAVE MORE SEVERE CONGENITAL HEART DEFECTS. TO CREATE A SET OF IN VITRO TOOLS FOR THE STUDY OF PARENT-OF-ORIGIN EFFECTS, JAX GENERATED MOUSE ES CELL LINES WITH PATERNALLY DERIVED TS65DN CHROMOSOMES AS WELL AS MATERNALLY DERIVED TS65DN CHROMOSOMES. THESE ES CELLS CAN BE USED TO STUDY THE UNDERLYING MECHANISMS OF PARENT-OF-ORIGIN EFFECTS IN THE CONTEXT OF DOWN SYNDROME, PARTICULARLY IN IN VITRO DIFFERENTIATED CARDIOMYOCTES. INFORMATICS - ONE OF THE GOALS OF JAX IS TO PROVIDE INFORMATION TO SUPPORT THE USE OF MOUSE MODELS IN BIOMEDICAL RESEARCH. TO THIS END, JAX CURATES THE JAXMICE DATABASE WHICH CONTAINS A "STRAIN DATASHEET" FOR EACH JAX STRAIN INCLUDING A STRAIN DESCRIPTION, GENE AND ALLELE INFORMATION, RESEARCH APPLICATIONS, AND A LIST OF PUBLICATIONS DESCRIBING THE MOUSE, AS WELL AS LINKS TO GENOTYPING PROTOCOLS, HEALTH REPORTS, AND ADDITIONAL INFORMATION IN MOUSE GENOME INFORMATICS (MGI), PUBMED, AND OTHER WEB RESOURCES. JAX ALSO PROVIDES TECHNICAL INFORMATION ON WEB PAGES HIGHLIGHTING JAX RESOURCES BY RESEARCH OR DISEASE AREA. GIVEN THE STEADY ACQUISITION OF NEW STRAINS, WE ARE CONTINUALLY ADDING NEW DATASHEETS AND UPDATING WEBPAGES TO REFLECT NEW RESOURCES AVAILABLE. AS FORM 990 REVIEW PROCESS FORM 990, PART VI, SECTION B, QUESTION 11A THE AUDIT COMMITTEE OF THE JACKSON LABORATORY'S BOARD OF TRUSTEES REVIEWS A DRAFT COPY OF THE IRS FORM 990 BEFORE IT IS PROVIDED TO THE BOARD OF TRUSTEES. AFTER THE AUDIT COMMITTEE'S REVIEW, THE IRS FORM 990 IS FINALIZED AND PROVIDED TO THE BOARD OF TRUSTEES AND FILED. CONFLICT OF INTEREST POLICY FORM 990, PART VI, SECTION B, QUESTION 12C THE JACKSON LABORATORY PROVIDES ALL OFFICERS, BOARD MEMBERS AND KEY EMPLOYEES WITH A CONFLICT OF INTEREST, CODE OF ETHICS AND DISCLOSURE FORMS AS WELL AS THE DISTRIBUTION OF ALL POLICIES REGARDING THE CONFLICT OF INTEREST AND CODE OF ETHICS. THIS PROCESS IS DONE ANNUALLY. THE DISCLOSURE AND COMPLIANCE ATTESTATIONS ARE RETURNED TO THE GENERAL COUNSEL, WHERE THEY ARE RECORDED AND TALLIED FOR COMPLETENESS. DISCLOSURES, AS WELL AS ANY FOLLOW UP QUESTIONS, ARE ROUTED THROUGH GENERAL COUNSEL, AND IF NECESSARY THE AUDIT COMMITTEE. COMPENSATION POLICY FORM 990, PART VI, SECTION B, QUESTION 15B THE COMPENSATION AND HUMAN RESOURCES COMMITTEE OF THE BOARD OF TRUSTEES SETS COMPENSATION AND BENEFITS FOR THE CHIEF EXECUTIVE OFFICER, EXECUTIVE VICE PRESIDENT AND CHIEF OPERATING OFFICER, THE VICE PRESIDENT OF RESEARCH, THE VICE PRESIDENT OF EXTERNAL AFFAIRS AND STRATEGIC PARTNERSHIPS, THE CHIEF FINANCIAL OFFICER AND EQUIVALENT POSITIONS AS WELL AS ANY OTHER EMPLOYEES OF THE LABORATORY WHO WOULD BE CONSIDERED 'INSIDERS' OR 'DISQUALIFIED PERSONS' WITHIN THE MEANING OF THE INTERMEDIATE SANCTIONS RULES UNDER THE INTERNAL REVENUE CODE. MEMBERS OF THE COMMITTEE ARE INDEPENDENT TRUSTEES SELECTED BY THE CHAIR OF THE BOARD OF TRUSTEES. THE COMMITTEE IS GUIDED BY MARKET DATA OF COMPENSATION PACKAGES FOR SIMILAR POSITIONS IN COMPARABLE ORGANIZATIONS. MARKET DATA IS PREPARED FOR THE COMMITTEE BY AN EXTERNAL EXECUTIVE COMPENSATION FIRM WHICH CONSIDERS COMPENSATION INFORMATION REPORTED IN FORM 990'S OF COMPARABLE ORGANIZATIONS AND THE RESULTS OF RECOGNIZED COMPENSATION SURVEYS. THE SENIOR DIRECTOR OF HUMAN RESOURCES IS AVAILABLE TO THE COMMITTEE TO PROVIDE ANY OTHER DATA NEEDED. THE CEO MEETS WITH THE COMMITTEE AT LEAST ANNUALLY TO PROVIDE THE COMMITTEE MEMBERS WITH ANNUAL PERFORMANCE REVIEWS OF HIS REPORTS. THE COMMITTEE'S REVIEW PROCESS AND RESULTS ARE DOCUMENTED IN MINUTES OF THE MEETINGS. PUBLIC DISCLOSURE FORM 990, PART VI, SECTION C, QUESTION 19 THE ORGANIZATION'S FORM 990 IS AVAILABLE ON WWW.GUIDESTAR.ORG AND ON THE ORGANIZATION'S PUBLIC WEBSITE WWW.JAX.ORG. THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS ALSO AVAILABLE WWW.JAX.ORG. OTHER CHANGES IN NET ASSETS FORM 990, PART XI, LINE 9 UNREALIZED LOSS ON INTEREST RATE SWAPS (1,461,708) CHANGES IN ACTUARIAL ASSUMPTIONS 79,795 FAIR MARKET VALUE ADJUSTMENT ON LOANS 41,837,090 TOTAL 40,455,177 SECURED MORTGAGES AND NOTES PAYABLE FORM 990, PART X, LINE 23 REPAYMENT TERMS THE CT INNOVATIONS LOANS WILL BE FORGIVEN IF AND WHEN THE LABORATORY MEETS AN EMPLOYMENT GOAL OF AT LEAST 300 EMPLOYEES LOCATED IN CONNECTICUT FOR A PERIOD OF SIX MONTHS, INCLUDING A MINIMUM OF 90 SENIOR SCIENTISTS. IN ADDITION, THE AVERAGE WAGE FOR SUCH EMPLOYEES MUST EXCEED A MINIMUM TARGET LEVEL.